CD274 and neoplasm: Comparing chemotherapy plus nivolumab with chemotherapy alone for the primary endpoint (tumor cell PD-L1 (TPS) ≥ 1%, n = 315) OS was significantly prolonged (median OS 15.4 versus 9.1 mths, HR 0.54; 99.5% CI 0.37–0.80; p < 0.0001).